Horizon Kinetics Asset Management LLC cut its stake in Johnson & Johnson (NYSE:JNJ – Get Rating) by 0.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,691 shares of the company’s stock after selling 77 shares during the period. Horizon Kinetics Asset Management LLC’s holdings in Johnson & Johnson were worth $3,302,000 at the end of the most recent reporting period.
Other institutional investors have also recently added to or reduced their stakes in the company. Mawer Investment Management Ltd. raised its holdings in shares of Johnson & Johnson by 3.8% during the fourth quarter. Mawer Investment Management Ltd. now owns 4,379,611 shares of the company’s stock worth $773,658,000 after purchasing an additional 160,427 shares during the period. Thoroughbred Financial Services LLC raised its holdings in shares of Johnson & Johnson by 2.2% during the fourth quarter. Thoroughbred Financial Services LLC now owns 39,462 shares of the company’s stock worth $6,971,000 after purchasing an additional 846 shares during the period. CPA Asset Management LLC acquired a new stake in shares of Johnson & Johnson during the fourth quarter worth $1,956,000. Zevin Asset Management LLC acquired a new stake in shares of Johnson & Johnson during the fourth quarter worth $207,000. Finally, Commonwealth Equity Services LLC raised its holdings in shares of Johnson & Johnson by 1.5% during the fourth quarter. Commonwealth Equity Services LLC now owns 1,769,186 shares of the company’s stock worth $312,526,000 after purchasing an additional 26,167 shares during the period. 67.94% of the stock is owned by institutional investors and hedge funds.
Johnson & Johnson Price Performance
Shares of NYSE JNJ opened at $161.05 on Wednesday. Johnson & Johnson has a twelve month low of $150.11 and a twelve month high of $183.35. The company has a current ratio of 1.07, a quick ratio of 0.85 and a debt-to-equity ratio of 0.49. The company has a market capitalization of $418.53 billion, a price-to-earnings ratio of 33.69, a PEG ratio of 2.78 and a beta of 0.53. The firm has a 50-day moving average of $158.62 and a two-hundred day moving average of $166.91.
Johnson & Johnson Increases Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 6th. Shareholders of record on Tuesday, May 23rd will be paid a dividend of $1.19 per share. The ex-dividend date of this dividend is Monday, May 22nd. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.13. This represents a $4.76 dividend on an annualized basis and a yield of 2.96%. Johnson & Johnson’s dividend payout ratio is currently 94.56%.
Analysts Set New Price Targets
A number of analysts have weighed in on the stock. Atlantic Securities dropped their target price on shares of Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating on the stock in a report on Wednesday, April 19th. Raymond James lowered their price target on shares of Johnson & Johnson from $185.00 to $181.00 and set an “outperform” rating for the company in a research report on Wednesday, April 19th. UBS Group assumed coverage on shares of Johnson & Johnson in a research report on Tuesday, March 28th. They set a “neutral” rating and a $164.00 price target for the company. Morgan Stanley upped their price target on shares of Johnson & Johnson from $179.00 to $183.00 and gave the stock an “equal weight” rating in a research report on Wednesday, April 19th. Finally, SVB Leerink lowered their price target on shares of Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating for the company in a research report on Friday, January 20th. Seven equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and an average target price of $173.00.
Insider Buying and Selling at Johnson & Johnson
In other Johnson & Johnson news, insider James D. Swanson sold 1,062 shares of the company’s stock in a transaction dated Monday, March 6th. The shares were sold at an average price of $154.66, for a total transaction of $164,248.92. Following the completion of the sale, the insider now directly owns 9,215 shares of the company’s stock, valued at $1,425,191.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders own 0.20% of the company’s stock.
About Johnson & Johnson
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
Read More
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- How to Buy Southwest Airlines Stock
- Lucid Group Bottomed, But The Outlook Remains Cloudy
- Shoals Technology is an EV and Solar Play Just Getting Started
- Under Armour May Have Just Bottomed
- Skyworks Solutions: Another Crack in the Consumer Outlook
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
